Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Guidelines

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type I (MPS I) under the Life Saving Drugs Program.

Downloads

Life Saving Drugs Program – Mucopolysaccharidosis type I (MPS I) – Guidelines

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date:
Last updated:
Publication type:
Guideline
Audience:
Health sector
Language:
English
Description:

These guidelines include:

  • General information about the Life Saving Drugs Program (LSDP)
  • Treatment of mucopolysaccharidosis type I (MPS I) through the LSDP
  • Drugs currently available for the treatment of MPS I through the LSDP
  • Dosage
  • General, initial and ongoing eligibility requirements
  • LSDP funding conditions
  • Exclusion criteria.

Help us improve health.gov.au

If you would like a response please use the enquiries form instead.